Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib Continuation Protocol for SLE, SjD, PsO, and PsA
NCT07791199Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2026
- Primary completion
- Oct 2030
01
Overview
A Phase 3 trial of deucravacitinib in systemic lupus erythematosus (SLE), Sjögren's syndrome, psoriasis, psoriatic arthritis (PsA), sponsored by Bristol Myers Squibb. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromepsoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07791199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791199.